|
1
|
Yousef YA, Soliman SE, Astudillo PPP,
Durairaj P, Dimaras H, Chan HSL, Héon E, Gallie BL and Shaikh F:
Intra-arterial chemotherapy for retinoblastoma: a systematic
review. JAMA Ophthalmol. Mar 17–2016.(Epub ahead of print).
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shields CL, Lally SE, Leahey AM, Jabbour
PM, Caywood EH, Schwendeman R and Shields JA: Targeted
retinoblastoma management: When to use intravenous, intra-arterial,
periocular, and intravitreal chemotherapy. Curr Opin Ophthalmol.
25:374–385. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Abramson DH, Shields CL, Munier FL and
Chantada GL: Treatment of retinoblastoma in 2015: Agreement and
disagreement. JAMA Ophthalmol. 133:1341–1347. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Beck WT, Mo YY and Bhat UG: Cytotoxic
signalling by inhibitors of DNA topoisomerase II. Biochem Soc
Trans. 29:702–703. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Clifford B, Beljin M, Stark GR and Taylor
WR: G2 arrest in response to topoisomerase II inhibitors: The role
of p53. Cancer Res. 63:4074–4081. 2003.PubMed/NCBI
|
|
6
|
Yuan L, Yu WM and Qu CK: DNA
damage-induced G2/M checkpoint in SV40 large T antigen-immortalized
embryonic fibroblast cells requires SHP-2 tyrosine phosphatase. J
Biol Chem. 278:42812–42820. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Villegas VM, Hess DJ, Wildner A, Gold AS
and Murray TG: Retinoblastoma. Curr Opin Ophthalmol. 24:581–588.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Griegel S, Hong C, Frötschl R, Hülser DF,
Greger V, Horsthemke B and Rajewsky MF: Newly established human
retinoblastoma cell lines exhibit an ‘immortalized’ but not an
invasive phenotype in vitro. Int J Cancer. 46:125–132. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reid TW, Albert DM, Rabson AS, Russell P,
Craft J, Chu EW, Tralka TS and Wilcox JL: Characteristics of an
established cell line of retinoblastoma. J Natl Cancer Inst.
53:347–360. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McFall RC, Sery TW and Makadon M:
Characterization of a new continuous cell line derived from a human
retinoblastoma. Cancer Res. 37:1003–1010. 1977.PubMed/NCBI
|
|
11
|
Stephan H, Boeloeni R, Eggert A, Bornfeld
N and Schueler A: Photodynamic therapy in retinoblastoma: Effects
of verteporfin on retinoblastoma cell lines. Invest Ophthalmol Vis
Sci. 49:3158–3163. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Haubold M, Weise A, Stephan H and Dünker
N: Bone morphogenetic protein 4 (BMP4) signaling in retinoblastoma
cells. Int J Biol Sci. 6:700–715. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Philippeit C, Busch M and Dünker N:
Epigenetic control of trefoil factor family (TFF) peptide
expression in human retinoblastoma cell lines. Cell Physiol
Biochem. 34:1001–1014. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Busch M, Philippeit C, Weise A and Dünker
N: Re-characterization of established human retinoblastoma cell
lines. Histochem Cell Biol. 143:325–338. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zijlstra A, Mellor R, Panzarella G, Aimes
RT, Hooper JD, Marchenko ND and Quigley JP: A quantitative analysis
of rate-limiting steps in the metastatic cascade using
human-specific real-time polymerase chain reaction. Cancer Res.
62:7083–7092. 2002.PubMed/NCBI
|
|
16
|
Palmer TD, Lewis J and Zijlstra A:
Quantitative analysis of cancer metastasis using an avian embryo
model. J Vis Exp. 51:28152011.
|
|
17
|
Weise A and Dünker N: High trefoil factor
1 (TFF1) expression in human retinoblastoma cells correlates with
low growth kinetics, increased cyclin-dependent kinase (CDK)
inhibitor levels and a selective down-regulation of CDK6. Histochem
Cell Biol. 139:323–338. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Elso CM, Roberts LJ, Smyth GK, Thomson RJ,
Baldwin TM, Foote SJ and Handman E: Leishmaniasis host response
loci (lmr1-3) modify disease severity through a Th1/Th2-independent
pathway. Genes Immun. 5:93–100. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Busch M and Dünker N: Trefoil factor
family peptides - friends or foes? Biomol Concepts. 6:343–359.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Żuryń A, Krajewski A, Szulc D, Litwiniec A
and Grzanka A: Activity of cyclin B1 in HL-60 cells treated with
etoposide. Acta Histochem. 118:537–543. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Helmbach H, Kern MA, Rossmann E, Renz K,
Kissel C, Gschwendt B and Schadendorf D: Drug resistance towards
etoposide and cisplatin in human melanoma cells is associated with
drug-dependent apoptosis deficiency. J Invest Dermatol.
118:923–932. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kerbel RS, St Croix B, Florenes VA and Rak
J: Induction and reversal of cell adhesion-dependent multicellular
drug resistance in solid breast tumors. Hum Cell. 9:257–264.
1996.PubMed/NCBI
|
|
23
|
Gravelle P, Jean C, Familiades J, Decaup
E, Blanc A, Bezombes-Cagnac C, Laurent C, Savina A, Fournié JJ and
Laurent G: Cell growth in aggregates determines gene expression,
proliferation, survival, chemoresistance, and sensitivity to immune
effectors in follicular lymphoma. Am J Pathol. 184:282–295. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
St Croix B and Kerbel RS: Cell adhesion
and drug resistance in cancer. Curr Opin Oncol. 9:549–556. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fogel M, Gutwein P, Mechtersheimer S,
Riedle S, Stoeck A, Smirnov A, Edler L, Ben-Arie A, Huszar M and
Altevogt P: L1 expression as a predictor of progression and
survival in patients with uterine and ovarian carcinomas. Lancet.
362:869–875. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gavert N, Conacci-Sorrell M, Gast D,
Schneider A, Altevogt P, Brabletz T and Ben-Ze'ev A: L1, a novel
target of beta-catenin signaling, transforms cells and is expressed
at the invasive front of colon cancers. J Cell Biol. 168:633–642.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cho S, Lee TS, Song IH, Kim AR, Lee YJ,
Kim H, Hwang H, Jeong MS, Kang SG and Hong HJ: Combination of
anti-L1 cell adhesion molecule antibody and gemcitabine or
cisplatin improves the therapeutic response of intrahepatic
cholangiocarcinoma. PLoS One. 12:e01700782017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jo DH, Lee K and Kim JH, Jun HO, Kim Y,
Cho YL, Yu YS, Min JK and Kim JH: L1 increases adhesion-mediated
proliferation and chemoresistance of retinoblastoma. Oncotarget.
8:15441–15452. 2017.PubMed/NCBI
|
|
29
|
Szakács G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Longley DB and Johnston PG: Molecular
mechanisms of drug resistance. J Pathol. 205:275–292. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu CP, Calcagno AM and Ambudkar SV:
Reversal of ABC drug transporter-mediated multidrug resistance in
cancer cells: Evaluation of current strategies. Curr Mol Pharmacol.
1:93–105. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kachalaki S, Baradaran B, Majidi J,
Yousefi M, Shanehbandi D, Mohammadinejad S and Mansoori B: Reversal
of chemoresistance with small interference RNA (siRNA) in etoposide
resistant acute myeloid leukemia cells (HL-60). Biomed
Pharmacother. 75:100–104. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu DD, Li XS, Meng XN, Yan J and Zong ZH:
MicroRNA-873 mediates multidrug resistance in ovarian cancer cells
by targeting ABCB1. Tumour Biol. 37:10499–10506. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chan HS, Thorner PS, Haddad G and Gallie
BL: Multidrug-resistant phenotype in retinoblastoma correlates with
P-glycoprotein expression. Ophthalmology. 98:1425–1431. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chan HS, Lu Y, Grogan TM, Haddad G,
Hipfner DR, Cole SP, Deeley RG, Ling V and Gallie BL: Multidrug
resistance protein (MRP) expression in retinoblastoma correlates
with the rare failure of chemotherapy despite cyclosporine for
reversal of P-glycoprotein. Cancer Res. 57:2325–2330.
1997.PubMed/NCBI
|
|
36
|
Filho JPS, Correa ZM, Odashiro AN,
Coutinho AB, Martins MC, Erwenne CM and Burnier MN Jr:
Histopathological features and P-glycoprotein expression in
retinoblastoma. Invest Ophthalmol Vis Sci. 46:3478–3483. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jia M, Wei Z, Liu P and Zhao X: Silencing
of ABCG2 by microRNA-3163 inhibits multidrug resistance in
retinoblastoma cancer stem cells. J Korean Med Sci. 31:836–842.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang D, Zhu Q, Zhang X, Zhang L, He Q and
Yang B: Hypoxia promotes etoposide (VP-16) resistance in
neuroblastoma CHP126 cells. Pharmazie. 65:51–56. 2010.PubMed/NCBI
|
|
39
|
Sudhakar J, Venkatesan N, Lakshmanan S,
Khetan V, Krishnakumar S and Biswas J: Hypoxic tumor
microenvironment in advanced retinoblastoma. Pediatr Blood Cancer.
60:1598–1601. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gao Y, Jing M, Ge R and Lang L: Induction
of hypoxia-inducible factor-1α by BDNF protects retinoblastoma
cells against chemotherapy-induced apoptosis. Mol Cell Biochem.
414:77–84. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Song HB, Jun HO and Kim JH, Yu YS, Kim KW,
Min BH and Kim JH: Anti-apoptotic effect of clusterin on
cisplatin-induced cell death of retinoblastoma cells. Oncol Rep.
30:2713–2718. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Magee P, Shi L and Garofalo M: Role of
microRNAs in chemoresistance. Ann Transl Med. 3:3322015.PubMed/NCBI
|
|
43
|
Ayers D and Vandesompele J: Influence of
microRNAs and long non-coding RNAs in cancer chemoresistance.
Genes. 8:pii: E952017. View Article : Google Scholar
|
